This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Steroid Injection Treatment of Carpal Tunnel Syndrome

This study has been completed.
Information provided by (Responsible Party):
Region Skane Identifier:
First received: December 10, 2008
Last updated: April 3, 2012
Last verified: March 2011
The aim of this study is to assess the efficacy of injecting steroid into the carpal tunnel in relieving symptoms of carpal tunnel syndrome for at least 1 year with outcomes measured with patient evaluated symptoms score.Out of the patients referred by primary care, those with a clinical diagnosis of CTS who have tried wrist splint and whose symptom severity is judged by the examining surgeon to warrant surgery are offered to be put on the waiting list for carpal tunnel release. This means a waiting time of approximately 3 months. Patients who give informed consent will be asked to attend the outpatient clinic for a physical examination followed by allocation to one of the three trial groups. Immediately following the allocation the patients will receive the assigned treatment.

Condition Intervention Phase
Carpal Tunnel Syndrome Drug: Methylprednisolone 40 mg Drug: Methylprednisolone 80 mg Drug: Sodium chloride Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Local Steroid Injection in the Treatment of Idiopathic Carpal Tunnel Syndrome: A Randomized Double-blind Placebo-controlled Trial Among Patients Planned for Surgical Treatment

Resource links provided by NLM:

Further study details as provided by Region Skane:

Primary Outcome Measures:
  • The CTS symptom severity score after treatment. [ Time Frame: 10 weeks ]
  • Rate of surgery [ Time Frame: 52 weeks ]

Secondary Outcome Measures:
  • The CTS symptom severity score after treatment [ Time Frame: 52 weeks ]
  • Time to surgery [ Time Frame: 52 weeks ]
  • QuickDASH score [ Time Frame: 52 weeks ]
  • SF-6D score [ Time Frame: 52 weeks ]
  • Patient satisfaction with the results of treatment (VAS scale) [ Time Frame: 52 weeks ]
  • Registration of adverse events [ Time Frame: 24 weeks ]

Enrollment: 112
Study Start Date: November 2008
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A Drug: Methylprednisolone 40 mg

Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use

1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline

Other Name: Depo-medrol
Active Comparator: B Drug: Methylprednisolone 80 mg

Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.

2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine

Other Name: Depo-medrol
Placebo Comparator: C Drug: Sodium chloride

Saline solution 0,9%, injection in the carpal tunnel, one time use

1 ml 10 mg Lidocaine + 2 ml saline

Other Names:
  • Saline
  • NaCl

Detailed Description:

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary, idiopathic CTS
  • Age 18-70 years, either gender
  • Symptom duration of at least 3 months and inadequate response to wrist splint
  • Symptoms of classic or probable CTS according to the diagnostic criteria in Katz hand diagram
  • Nerve conduction studies showing median neuropathy at the wrist and no other abnormalities or, in the absence of abnormal nerve conduction study results, 2 surgeons should independently diagnose the patient with CTS.
  • Scheduled for carpal tunnel release (ie, symptom severity indicating need for surgery)exclusion criteria

Exclusion Criteria:

  • Previous steroid injection for CTS in the same wrist
  • Inflammatory joint disease, diabetes mellitus· Vibration-induced neuropathy, polyneuropathy
  • Pregnancy
  • Trauma to the affected hand in the previous year
  • Previous CTS surgery in the affected hand
  • Inability to complete questionnaires due to language problem or cognitive disorder
  • Severe medical illness
  • Known abuse of drugs and/or alcohol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00806871

Ortopediska kliniken, sjukvårdsorganisationen Hässleholm/CSK
Hässleholm, Sweden, 281 25
Sponsors and Collaborators
Region Skane
Study Chair: Isam Atroshi, MD, PhD Lund university, department of clinical sciences, Hässleholm hospital, department of orthopedics
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Region Skane Identifier: NCT00806871     History of Changes
Other Study ID Numbers: prövningsprotokoll 080723
Study First Received: December 10, 2008
Last Updated: April 3, 2012

Additional relevant MeSH terms:
Carpal Tunnel Syndrome
Pathologic Processes
Median Neuropathy
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Nerve Compression Syndromes
Cumulative Trauma Disorders
Sprains and Strains
Wounds and Injuries
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents processed this record on September 19, 2017